Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

← catalyst calendar

NCT04454437

Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

80actual

Sites

Country

China

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-10-23

actual

When the study began enrolling

Primary completion

2021-08-06

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2027

estimated

The whole study's end, after follow-up

First posted

2020-07-01

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-02-02

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Metastatic Triple-negative Breast Cancer

Intervention

Drug: Sacituzumab Govitecan-hziy — also filed as IMMU-132, Trodelvy™, GS-0132

Primary outcome

what the primary-completion date above is the date OF

Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Independent Review Committee (IRC)

measured Up to 3 years

Publications

PMID 36621000 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed